AndhraNews.net
Home » Business News » 2013 » February » February 13, 2013

Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss


February 13, 2013 - Stockholm, Sweden

Sobi (STO: Sobi) announced that it hasentered into a distribution agreement with PharmaSwiss to market theproductsMegace®, Monopril®, Cefzil® and Duricef® approved forthe treatment ofindications within the oncology, cardio-vascular and anti-infective therapyareas. Under the terms of the agreement, Sobi will have distribution rightsinIreland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden,Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal,andLuxembourg. All products are approved within the Sobi territory, wheresales in2012 were approximately SEK 120 million (EUR 14 million). Sobi expects toinitiate distribution for the portfolio by the end of the first quarter2013.

Anders Edvell, Vice President and Head of Partner Products at Sobi, said:"Wehave built a unique European platform with Partner Products to support thecomplex clinical and reimbursement requirements of niche and specialtyproducts. We are delighted to be able to provide patients and physicianswiththis portfolio of important treatment options, and to welcome PharmaSwissas anew partner."

About Megace® (megestrol): Megace is a progestogen hormone drug isindicatedfor the treatment of certain hormone-dependent neoplasms such as breastcancer.

About Monopril® (fosinopril): Monopril is an angiotensin convertingenzyme(ACE) inhibitor indicated for treatment of hypertension and congestiveheartfailure.

About Cefzil® (cefprozil): Cefzil is a broad-spectrum cephalosporinantibioticindicated for the treatment of mild to moderate infections.

About Duricef® (cefadroxil): Duricef is a cephalosporin antibioticindicatedfor the treatment of urinary tract infections, skin infections, pharyngitisand/or tonsillitis, where the infections are caused by susceptible strainsofdesignated microorganisms.

About Sobi Partner Products

Sobi Partner Products (SPP) is a business unit within Sobi which offers auniquecommercial platform for partners with niche and specialty products. SPPprovidesextensive knowledge and local experience through our direct presence acrossEU,Eastern Europe, Russia, Middle East and North Africa. We apply anintegratedcommercial, medical, and market access approach to products which addressimportant unmet needs, working from named patient use (NPU) programsthrough toreimbursement and commercialization, primarily in the Centre of Expertisesetting. The key SPP therapeutic areas are Oncology, Hematology, InfectiousDiseases, and Emergency Medicines & Antidotes.

About Sobi

Sobi is an international specialty healthcare company dedicated to rarediseases. Our mission is to develop and deliver innovative therapies andservices to improve the lives of patients. The product portfolio isprimarilyfocused on inflammation and genetic diseases, with three late stagebiologicaldevelopment projects within hemophilia and neonatology. We also market morethan40 specialty and rare disease products for partner companies. Sobi is apioneerin biotechnology with world-class capabilities in protein biochemistry andbiologics manufacturing. In 2011, Sobi had total revenues of SEK 1.9billion (EUR214 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQOMXStockholm. More information is available at www.sobi.com.

The information above has been published pursuant to the Swedish SecuritiesMarket Act and/or the Financial Instruments Trading Act. The informationwasreleased for public distribution on February 13, 2013 at 08:30 a.m. CET.

Sobi Press Release on February 13, 2013, in PDF format:http://hugin.info/134557/R/1677552/547139.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE

[HUG#1677552]

Contact at Sobi
Anders Edvell
Vice President and Head of Partner Products
Phone: +46 8 697 2000

Jorgen Winroth
Vice President Investor Relations
Phone: +46 8 6973427

MarketWire

Comment on this story

Share